Asymptomatic Hypertrophic Cardiomyopathy: Diagnosis and Therapy

Virginia Luis Fuentes; Lois J Wilkie

doi:10.1016/j.cvsm.2017.05.002

Asymptomatic Hypertrophic Cardiomyopathy: Diagnosis and Therapy

Vet Clin North Am Small Anim Pract. 2017 Sep;47(5):1041-1054. doi: 10.1016/j.cvsm.2017.05.002. Epub 2017 Jun 27.

Authors

Virginia Luis Fuentes¹, Lois J Wilkie²

Affiliations

¹ Department of Clinical Science and Services, The Royal Veterinary College, Hawkshead Lane, North Mymms, Hatfield, Hertfordshire AL9 7TA, UK. Electronic address: vluisfuentes@rvc.ac.uk.
² Vets4Pets, 66 Cornard Road, Sudbury, Suffolk CO10 2XB, UK.

PMID: 28662873
DOI: 10.1016/j.cvsm.2017.05.002

Abstract

Hypertrophic cardiomyopathy (HCM) affects 15% of cats, and prevalence increases with age. Although many cats with HCM have normal life expectancy, some cats die suddenly, or develop congestive heart failure or arterial thromboembolism (ATE). High-risk cats can be recognized by left atrial enlargement on echocardiography, which can be missed on physical examination, as a heart murmur is often absent. Alternatively, plasma biomarkers can be measured as an initial screening test; echocardiography is indicated in cats with plasma NT-probrain natriuretic peptide concentrations exceeding 100 pmol/L. High-risk cats should be treated with clopidogrel to reduce the risk of ATE.

Keywords: Biomarkers; Cats; Dynamic outflow tract obstruction; Echocardiography; Risk; Screening; Thromboembolism.

Publication types

Review

MeSH terms

Animals
Biomarkers
Cardiomyopathy, Hypertrophic / diagnosis
Cardiomyopathy, Hypertrophic / therapy
Cardiomyopathy, Hypertrophic / veterinary*
Cat Diseases / diagnosis*
Cat Diseases / therapy*
Cats
Echocardiography
Heart Failure / diagnosis
Heart Failure / therapy
Heart Failure / veterinary

Substances

Biomarkers